Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03161223
Title Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Columbia University

peripheral T-cell lymphoma


Durvalumab + Romidepsin

Azacitidine + Durvalumab

Azacitidine + Durvalumab + Romidepsin

Durvalumab + Pralatrexate + Romidepsin

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.